Kindred Biosciences, Inc. is a development-stage biopharmaceutical company that develops therapies for pets, such as dogs, cats and horses. The Company’s lead product candidates are SentiKind, which completed clinical studies, is used to treat post-operative pain in dogs, KIND-010, conducting pilot studies, manages weight loss in cats, and KIND-012, conducting pilot studies, treats fever in horses. Its other product candidates include KIND-502, a discovery and process development stage biologic for allergic diseases in dogs; KIND-506/509, a manufacturing process development stage biologic for inflammatory diseases in dogs; KIND-507, a manufacturing process development stage biologic for autoimmune diseases in dogs; KIND-504, a manufacturing process development stage cancer vaccine for cancer in dogs; KIND-501, a discovery and process development stage antiangiogenic biologic for cancer in dogs, and KIND-510, a manufacturing process development stage Feline Epo for anemia in cats.
